News
3d
Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in ...
Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic ...
Elutia’s Roswell facility is FDA-registered as a medical device manufacturing establishment and has not experienced any delays, cost increases, or supplier issues related to the tariffs. The Company ...
Hosted on MSN25d
Elutia Inc. secures $15 million through stock and warrant saleSILVER SPRING, Md. - Elutia Inc. (NASDAQ:ELUT), a medical technology company with a current market capitalization of $111.29 million according to InvestingPro, disclosed today that it has ...
Elutia Inc. has announced the launch of a clinical study for EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs).
SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut ...
Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email IR@ ...
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams ...
SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ...
Elutia To Participate In Chardan’S Trending Issues In Drug Development Conference Series On April 29
A live and archived webcast of the fireside chat will be available in the“Investors” section of the Elutia website at . Elutia develops and commercializes drug-eluting biomatrix products to ...
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at http://investors.elutia.com/. About Elutia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback